Question 1

How does respiratory syncytial virus enter host cells?

Accepted Answer

RSV enters through the nasal mucosa via respiratory droplets. The viral envelope's G protein binds to cellular receptors on ciliated epithelial cells, while the F protein initiates fusion between viral and host membranes. This fusion allows the viral nucleocapsid to enter the host cell cytoplasm, beginning the infection cycle.

Question 2

What happens during the RSV replication cycle inside host cells?

Accepted Answer

After entry, RSV transcribes its RNA genome into mRNA, directing viral protein production for capsid assembly and genome replication. The virus uses the host's cellular machinery to complete replication in the cytoplasm. New virions then bud off from the host cell membrane to infect neighboring cells.

Question 3

Why does RSV infection cause breathing difficulties in children?

Accepted Answer

The host immune system releases inflammatory cytokines in response to RSV, damaging the respiratory lining. This causes cellular debris and mucus accumulation in the airways, obstructing airflow and impairing normal breathing. Epithelial necrosis and mucus hypersecretion further reduce lung compliance and mucociliary clearance.

Question 4

What are the structural features of respiratory syncytial virus?

Accepted Answer

RSV is an enveloped virus with a lipid bilayer encasing a ribonucleoprotein core. Its viral envelope displays two critical glycoproteins: the attachment glycoprotein (RSV-G) for initial adherence to host cells, and the fusion glycoprotein (RSV-F) for membrane fusion. These surface proteins are essential for viral entry and immune recognition.

Question 5

Who is most at risk for severe RSV disease?

Accepted Answer

Although RSV primarily targets infants and young children, elderly and immunocompromised individuals also face serious health risks. In young children, severe lower respiratory tract involvement such as bronchiolitis is common and can progress to pneumonia or respiratory failure. Globally, millions of cases result in hospitalizations and mortality, particularly in resource-limited settings.

Question 6

How do monoclonal antibodies help treat RSV infections?

Accepted Answer

Monoclonal antibodies such as palivizumab and nirsevimab target the fusion protein to prevent cellular entry and viral spread. By blocking the F protein's function, these therapeutic agents reduce the virus's ability to fuse with host membranes and establish infection, offering prophylactic protection for high-risk populations.

Question 7

What immune response occurs after RSV infection?

Accepted Answer

Host immune responses include early polymorphonuclear infiltration followed by lymphomononuclear responses. Viral replication and immune-mediated cytotoxicity lead to epithelial necrosis and mucus hypersecretion. While these responses attempt to control infection, they also contribute to airway obstruction and reduced lung function, similar to complications seen in cytomegalovirus disease.

مرض الفيروس المخلوي التنفسي

Browse More Videos